Catapult Therapeutics

**Catapult Therapeutics** is a Dutch-based **biotech company** that specializes in the development of **targeted cancer therapy**. Their flagship product, CAP-100, is an **innovative first-in-class humanized anti-CCR7 antibody**. Despite the absence of publicly available data regarding their founding date, the company has positioned itself as a prominent player in the biotechnology sector. Based in **The Netherlands**, the company is poised to make significant strides in the field of cancer treatment. In terms of investments, the latest funding details for Catapult Therapeutics are currently unavailable. While the specific investment amount and the involved investors remain undisclosed, the company's focus on pioneering cancer treatment solutions positions it as an attractive prospect for venture capitalists seeking to make a meaningful impact in the biotechnology industry. With its promising approach to targeted cancer therapy, Catapult Therapeutics presents an intriguing opportunity for investors looking to support innovative solutions in the fight against cancer.